- $31.89bn
- $33.90bn
- $9.89bn
Biogen Q1 revenue and adjusted EPS beat, lowers 2026 outlook
Brief: Biogen Q1 Adjusted EPS USD 3.57 Vs. IBES Estimate USD 2.77
Biogen cuts annual profit forecast on acquisition-related charges
Brief: Biogen Outlook FY Adjusted EPS $14.25 To $15.25 Vs IBES Estimate $15.04
U.S. RESEARCH ROUNDUP-CME Group, GE Vernova, Texas Instruments
U.S. STOCKS ON THE MOVE-Adobe, Biogen, Sable
U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO
U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma
Brief: Biogen Enters Into Agreement With Tj Biopharma For Felzartamab Assets In The Greater China Region
Biogen rises after buying China rights to kidney disease drug
US FDA's accelerated approval for drugs needs more transparency, says research firm (updated)
US FDA's accelerated approval for drugs needs more transparency, says research firm
U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines
U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma
Citi, Truist trim PT on Biogen ahead of Q1 earnings
Brief: Alloy Therapeutics Enters Into Multi-Target Collaboration And License Agreement With Biogen For Use Of Alloy’S Anticlastic™ Aso Platform
Brief: Biogen - Expects Q1 2026 GAAP And Non-GAAP EPS Impact Of $0.19 From Charge - SEC Filing